095700 — Genexine Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩288bn
- KR₩304bn
- KR₩4bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS/A | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 82,516 | 6,714 | 27,796 | 21,942 | 64,482 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4,320 | 8,345 | 2,440 | 13,779 | 16,642 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 95,817 | 20,646 | 57,274 | 52,384 | 92,160 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 49,839 | 71,856 | 111,969 | 110,932 | 114,209 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 358,177 | 596,908 | 636,865 | 388,781 | 376,587 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 22,638 | 40,217 | 59,154 | 78,933 | 54,526 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 61,267 | 61,303 | 122,937 | 112,627 | 79,965 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 296,909 | 535,605 | 513,928 | 276,154 | 296,622 |
Total Liabilities & Shareholders' Equity | 358,177 | 596,908 | 636,865 | 388,781 | 376,587 |
Total Common Shares Outstanding |